RxDoctor Payments Data

Ashley Brouwer

Adult Health · Fairbanks, AKNPI 1821256751

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,048 of the $2,488 with a category attached, or 82.3%. 26 manufacturers reported payments, led by Astellas Pharma US Inc at 25.9% of the total. Among adult health clinicians in AK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,488in general payments, 2019–2025

Across 82 payments — averaging $30.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$645
  • Sumitomo Pharma America, Inc.$385
  • Bayer$172
  • Teleflex LLC$157
  • 180 Medical, Inc.$156
  • AstraZeneca$125
  • plus $847 from 20 others

What the payments were for

  • Food & beverage$2,04882%
  • Education$44018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,488 in reported general payments places this provider in the 90th percentile of 22 adult health providers in Alaska.

See all adult health providers in Alaska

Medicare billing

Part B allowed, 2024
$130,653
Medicare patients
402
Services billed
4,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron198$217,471
MyrbetriqMirabegron62$58,415
Estradiol132$6,683
Testosterone Cypionate56$3,388
Solifenacin Succinate68$2,611
Tamsulosin Hcl123$2,161
Tolterodine Tartrate ErTolterodine Tartrate15$1,306
Cefdinir67$903
Anastrozole49$862
Finasteride52$624
Clobetasol Propionate12$301
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$242
Oxybutynin Chloride ErOxybutynin Chloride15$223
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet16$218
Levofloxacin44$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$385$217,471198 claims
Astellas Pharma US IncMyrbetriq$645$58,41562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 22 adult health providers in Alaska.

Other adult health in Fairbanks

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →